Agilent Announces Deals in South Korea for Clinical Assay Development, Neurometabolomic Research | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies separately announced on Thursday a collaboration with Samsung Medical Center and the creation of a new center for neurometabolomics in South Korea.

Under the terms of the deal with Samsung, the Department of Laboratory Medicine & Genetics Research in Seoul, South Korea — part of the Center for Future Medicine at Samsung Medical Center — will use bio-analytical instruments from Agilent for the analysis of clinical samples and to develop novel clinical assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.